Scleroderma - Developing measures of response

Journal of Rheumatology

Volumn 32, Issue 12, 2005, Pages 2477-2480

  Furst, Daniel E ^a,g   Khanna, Dinesh ^a,b   Mattucci Cerinic, Marco ^c   Silman, Alan J ^d   Merkel, Peter A ^e   Foeldvari, Ivan ^f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

^c UNIVERSITY OF FLORENCE   (Italy)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

^e BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f Pediatric Rheumatology Clinic at Ielbek

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Pediatric Scleroderma; Pulmonary; Renal; Response measures; Scleroderma; Skin

Indexed keywords

BLOOD PRESSURE MEASUREMENT; BLOOD VESSEL INJURY; CONFERENCE PAPER; GASTROINTESTINAL DISEASE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FUNCTION; MEDICAL RESEARCH; PRIORITY JOURNAL; PROTEINURIA; QUALITY OF LIFE; SCLERODERMA;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS; FINGERS; GASTROINTESTINAL DISEASES; GLOMERULAR FILTRATION RATE; HEALTH STATUS; HUMANS; KIDNEY DISEASES; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); QUALITY OF LIFE; RESEARCH DESIGN; SCLERODERMA, LOCALIZED; SCLERODERMA, SYSTEMIC; SKIN ULCER;

EID: 28844435638     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (14)

1. Boers M, Brooks P, Strand CV, Tugwell P. The OMERACT filter for Outcome Measures in Rheumatology. J Rheumatol 1998;25:198-9.
2. Merkel PA, Clements PJ, Reveille JD, Suarez-Almazor ME, Valentini G, Furst DE. Current status of outcome measure development for clinical trials in systemic sclerosis. Report from OMERACT 6. J Rheumatol 2003;30:1630-47.
3. Bombardieri S, Medsger TA Jr, Silman AJ, Valentini G. The assessment of the patient with systemic sclerosis. Clin Exp Rheumatol 2003;21 Suppl 29:S2-4.
4. Clements PJ. Systemic sclerosis (scleroderma) and related disorders: clinical aspects. Baillieres Best Pract Res Clin Rheumatol 2000;14:1-16.
5. Sjogren RW. Gastrointestinal features of scleroderma. Curr Opin Rheumatol 1996;8:569-75.
6. Guyatt G, Mitchell A, Irvine EJ, et al. A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology 1989;96:804-10.
7. Manterola C, Munoz S, Grande L, Bustos L. Initial validation of a questionnaire for detecting gastroesophageal reflux disease in epidemiological settings. J Clin Epidemiol 2002;55:1041-5.
8. Groll D, Vanner SJ, Depew WT, et al. The IBS-36: a new quality of life measure for irritable bowel syndrome. Am J Gastroenterol 2002;97:962-71.
9. Kingdon EJ, Knight CJ, Dustan K, et al. Calculated glomerular filtration rate is a useful screening to identify scleroderma patients with renal impairment. Rheumatology Oxford 2003;42:26-33
10. Hallan S, Asberg A, Lindberg M, Johnsen H. Validation of the Modification of Diet in Renal Disease formula for estimating GFR with special emphasis on calibration of the serum creatinine assay. Am J Kidney Dis 2004;44:939; author reply 939-40.
11. Livi R, Pignone A, Miniati I, Matucci-Cerinic M. Renal involvement in systemic sclerosis. Long term follow up of scleroderma patients: Evidence for modification of blood pressure and glomerular filtration rate (submitted).
12. Furst DE, Clements PJ, Wong WK, et al. Effects of the American College of Rheumatology systemic sclerosis trial guidelines on the nature of systemic sclerosis patients entering a clinical trial. Rheumatology Oxford 2001;40:615-22.
13. Akesson A, Fiori G, Krieg T, et al. Assessment of skin, joint, tendon and muscle involvement. Clin Exp Rheumatol 2003;21 Suppl 29:S5-S8.
14. Sato S, Hasegawa M, Takehara K. Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis. J Dermatol Sci 2001;27:140-6.